Author

B. L. Rodriguez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:bacteria (other)· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

D. L. Gibbons· 2 shared J. Wang· 2 shared L. A. Byers· 2 shared L. Diao· 2 shared A. Duarte· 1 shared A. G. Serrano· 1 shared A. N. Wambua· 1 shared A. Padhye· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. L. Gibbons

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Characterization of natural product inhibitors of quorum sensing in Pseudomonas aeruginosa reveals competitive inhibition of RhlR by ortho-vanillin

K. E. Woods, S. Akhter, B. L. Rodriguez, K. A. Townsend, N. C. Smith, A. N. Wambua, V. Craddock, E. E. Santa, D. E. Manson, R. G. Abisado-Duque, B. R. Oakley, L. E. Hancock, Y. Miao, H. E. Blackwell, J. R. Chandler

This study evaluates benzaldehyde derivatives as quorum sensing inhibitors in Pseudomonas aeruginosa, identifying ortho-vanillin as a competitive inhibitor of RhlR.

bioRxiv · Feb 24, 2024 · PreprintMicrobiology

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

C. A. Stewart, L. Diao, Y. Xi, R. Wang, K. Ramkumar, A. G. Serrano, B. L. Rodriguez, B. B. Morris, L. Shen, B. Zhang, Y. Yang, S. H. Hamad, R. J. Cardnell, A. Duarte, M. Sahu, , C. M. Gay

bioRxiv · Dec 19, 2023Cancer Biology

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

D. H. Peng, B. L. Rodriguez, L. Diao, P. O. Gaudreau, A. Padhye, J. K. Ochieng, C. A. Class, J. J. Fradette, L. A. Gibson, L. Chen, J. Wang, L. A. Byers, D. L. Gibbons

This study shows that Th17 cells contribute to resistance to MEK inhibitor and anti-PD-L1 therapy in KRAS/p53 mutant lung cancers and suggests a triple combinatorial therapy to overcome resistance.

bioRxiv · Jun 7, 2020Cancer Biology